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Abstract
Tuftsin is a tetrapeptide (Thr-Lys-Pro-Arg) that specifically binds
monocytes, macrophages, and polymorphonuclear leukocytes and potenti-
ates their natural killer activity against tumors and pathogens. The antimi-
crobial activity of this peptide is significantly increased by attaching at the
C-terminus a fatty acyl residue through the ethylenediamine spacer arm.
This activity is further augmented by incorporating the modified tuftsin in
the liposomes. The tuftsin-bearing liposomes not only enhance the host's
resistance against a variety of infections but also serve as useful vehicles
for the site-specific delivery of drugs in a variety of macrophage-based
infections, such as tuberculosis and leishmaniasis.
..
Introduction
Tuftsin is a macrophage natural killer activator tetrapeptide (Thr-Lys-
Pro-Arg) that is an integral part of the Fc portion of the heavy chain of
the leukophilic immunoglobulin G (residues 289-292) and is released
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physiologically as the free peptide after enzymatic cleavage (Najjar, 1987).
It is known to possess specific receptors on monocytes, macrophages, and
polymorphonuclear (PMN) leukocytes (Najjar, 1987) and potentiates the
natural killer activity of these cells against tumors and, presumably, also
against a variety of pathogens (Agrawal and Gupta, 2000). These proper-
ties of tuftsin make it an attractive candidate for use as a cell-specific ligand
for targeting of drugs to the pathogens that reside and proliferate within
macrophages and monocytes. Since these cells can be infected by a number
of pathogens, includingMycobacterium tuberculosisandLeishmania dono-
vani,and provide nonspecific resistance against a variety of infections, it is
expected that grafting of tuftsin on the surface of the liposomes that are
loaded with antibacterial/antiparasitic drugs should significantly increase
their therapeutic efficacy against these infections.
Tuftsin, due to its hydrophilic character, cannot be grafted on the
surface of liposomes without being attached to a sufficiently long hydro-
phobic anchor. Structure-function studies of this tetrapeptide indicate that
its binding and subsequent activation of the mononuclear phagocyte sys-
tem (MPS) is dependent upon rather strict conservation of its molecular
structure. Thus, modifications of the peptide at its N-terminus or within the
chain lead to a significant reduction or even loss of its biological activity
(Fridkin and Gottlieb, 1981). However, the activity is largely retained if
modifications are restricted only to the C-terminus (Gottliebet al., 1982).
All the modifications are, thus, limited to the carboxyl group of the Arg
residue. Direct attachment of a fatty acyl group to the Arg residue, without
any spacer arm, leads to modified tuftsin, which does not allow formation
of liposomes, presumably due to perturbation of the phospholipid polar
head group packing by the bulky Arg residue (Singhalet al.,1984). This
problem is, however, circumvented by introducing an ethylenediamine
spacer arm between the Arg residue and the hydrophobic anchor (Fig. 1).
Liposomes containing palmitoyl tuftsin (I) specifically recognize macro-
phages and PMN leukocytes (Singhalet al.,1984). Treatment of macro-
phages with these liposomes considerably increases their respiratory burst
activity (Singhet al.,1992). Pretreatment of animals with tuftsin-bearing
liposomes enables the animals to resist malaria (Guptaet al.,1986), leish-
mania (Guruet at.,1989), and fungal (Owaiset al.,1993) infections. In
addition, delivery of antileishmanial (Agrawalet at.,2002; Guruet al.,
Thr-Lys-Pro-Arg- NH-(CH2h- NH -C-C1sH31
II
o
FIG. 1. Structure of palmitoyl tuftsin (I).
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1989), antitubercular (Agarwalet l.,1994), antifungal (Owaiset al., 1993),
and antifilarial (Owaiset al.,2003) drugs in liposomes containing 1is shown
to increase the therapeutic efficacy of drugs against these infections.
Here, we describe procedures for preparation of 1 as well as the lipo-
somes that contain 1 in their bilayers, entrapment of various drugs in these
liposomes, and their delivery to experimental animals with infected
L. donovani, M. tuberculosis,orAspergillus.
~.
"
Synthesis of Palmitoyl Tuftsin (I)
Synthesis of 1 is carried out by the standard solution phase methods of
peptide synthesis. The first intermediate, HzN-(CHzh-NH-CO-ClSH31. is
prepared by reacting palmitoyl chloride with an excess of ethylenediamine
in a dilute ether solution. The amine thus obtained is coupled without
purification with t-butyloxycarbonyl (Boc)-Arg(NCz)-OH, using theN,
N-dicyc1ohexylcarbodiimide/ N-hydroxybenzotriazole (DCC/HOBt) proce-
dure. The poduct is purified by silica gel chromatography to obtain Boc-
Arg(NCz)-NH-CHz-CHz-NH-CO-ClSC31' The Boc group is removed by
treatment with 4N HCI in dioxane. The resulting amine hydrochloride is
then coupled with Boc-Pro-OH using DCC/HOBt to obtain the dipeptide
Boc-Pro-Arg(NOz)-NH-CHz-CHz-NH-CO-C1SH31 as a white powder. The
Boc group is removed by treatment with 4N HCI/dioxane, and the resulting
amine is coupled with Boc-Lys[benzyloxycarbonyl (Z)]-OH using benzo-
triazole-1-yl-oxy-tris-( dimethylamino )-phosphonium hexafluorophosphate
(BOP) reagent to obtain the tripeptide Boc-Lys(Z)-Pro-Arg(NOz)-NH-
CHz-CHz-NH-CO-ClSH31' Removal of the Boc group from the tripeptide
and subsequent coupling of the resulting amine with Boc-Thr[benzyl (Bz)]-
OH using BOP reagent affords the fully blocked tetrapeptide Boc-Thr
(Bz)-Lys(Z)-Pro-Arg(NOz)-NH-CHz-CHz-NH-CO-ClSH31' The crude tet-
rapeptide is purified by silica gel chromatography and crystallized from
ethylacetate/hexane. The tetrapeptide is treated with 4N HCl/dioxane to
remove the Boc group, and the resulting product is subjected to catalytic
hydrogenation over Pd black to obtain the desired compound as a white
powder. The detailed synthetic procedure is given below.
Preparation of H2N-CHrCH2-NH-CO-ClSH31 (II)
-. Palmitoyl chloride (2 ml) is added dropwise to a solution of ethylene-
diamine (5 ml; Sigma-Aldrich) in anhydrous ether (50 ml) at 0° under
vigorous stirring. A white precipitate separates out in the reaction mixture.
It is further stirred for 1.5 h, and then the precipitate is filtered and washed
with cold ether. The solid is taken in chloroform and washed with saline.
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The organic layer is dried over anhydrous sodium sulfate and concentrated
under reduced pressure to obtain HzN-CHz-CHz-NH-CO-C1SH31 as a gum-
my material (2.1 g). This product is dried over PzOs and KOH pellets under
vacuum and used as such without further purification. Fast atom bombard-
ment mass spectrometry (FAB-MS): nuclear magnetic resonanance MH+,
299; (NMR) (CDCI3)Dppm: 0.88 [triplet (t), 3H,C 3],1.24 [broad singlet
(bs), 26H,CHz],2.17 (t, 2H,CO-CHz),3.36 (bs, 4H,NH-CHz-CHz-NHz),
5.7-5.84 [broad hump (bh), NR].
Preparation of Boc-Arg (N02)-HN-CHrCHrNH-CO-C15H31 (III)
To a solution of Boc-Arg(NOz)-OH (2.1 g, 6.5mM) in anhydrous
dimethylformamide (DMF) (15 mI), HOBt (0.9 g,6.5mM;Janssen Chimi-
ca) is added, and the reaction mixture is cooled to 0°. To this solution DCC
(1.4 g, 7mM; Janssen Chimica) is added under vigorous stirring. After
10 min, a solution of D (2 g, 7mM) in dichloromethane (10 ml) is added,
and the reaction mixture is stirred for 1.5 h at 0° and then kept in a
refrigerator overnight. Dicyclohexylurea (DCU) is filtered, and the filtrate
is evaporated under reduced pressure. The residue is partitioned between
ethylacetate (100 ml) and saline (25 ml). The organic layer is washed with
5% citric acid (3 x 20 ml), saline (3 x 20 ml), 5% NaHC03 (3 x 20 ml),
and finally with saline. The organic layer is dried over anhydrous sodium
sulfate and concentrated under reduced pressure to obtain the crude com-
pound (3.2 g). The crude product is subjected to silica gel (Merck) chroma-
tography using 2% methanol (MeOH) in chloroform as the eluent to obtain
2.5 g chromatographically homogeneous compound. It is characterized
by mass and NMR spectroscopy. Melting point (M.P.) 120-121°;
[a]Dzs - 3.5 (c = 1, DMF); FAB-MS: MH+, 599; NMR (CDCh)ppm:
0.88 (t, 3H,CH3), 1.24 (bs, 26H,CHz), 1.4 [singlet (s), 9H], 1.68-1.79
(bs, 4H, (3and,CHz Arg), 2.17 (t, 2H,CO-CHz), 3.36 (bs, 6H,NH-CHz-
CHz-NH and D CHz Arg), 4.23 [multiplet (m), IH, a CR], 5.7-8.24
(bh, NH).
Preparation of Boc-Pro-Arg(N02)-HN-CHrCHrNH-CO-C15H31 (IV)
CompoundIII (3.0 g, 5mM) is dissolved in 4N HCl/dioxane (25 ml),
and the solution is kept at room temperature for 1.5 h. Solvent is removed
under reduced pressure, and the residue is precipitated by addition of an
excess of dry ether. The hydrochloride salt is collected by filtration and
washed with anhydrous ether three times. It is dried over PzCs and KOH
pellets in a vacuum desiccator.
To a solution of Boc-Pro-OH (1.1 g, 5.2mM) and HOBt (0.75 g,
5.5 mM) in dry DMF (25 ml) is added the hydrochloride saltof III,
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obtained as above, in dry DMF (15 ml) andN-methylmorpholine (1.2 ml)
at 4° under vigorous stirring. To this vigorously stirred mixture, DCC
(1.2 g, 6mM) in dry dichloromethane (10 ml) is added dropwise. The
reaction mixture is stirred further for 1.5 h at 0° and 8 h at room tempera-
ture. DCU is removed by filtration, and the filtrate is evaporated under
reduced pressure. The residue is extracted in ethylacetate (150 ml) and the
organic layer washed with 5% citric acid (3 x 20 ml), saline (3 x 20 ml),
5% NaHC03 (3 x 20 ml), and finally with saline. The organic layer is dried
over anhydrous sodium sulfate and concentrated under reduced pressure to
obtain an oily residue. The residue is crystallized with ethylacetate/hexane
to obtain chromatographically homogeneous IV as a white solid. Yield:
2.8 g (83%). It is characterized by mass and NMR spectroscopy. M. P. 140-
142°; [a]DZ5- 14.2 (c= 1.1,DMF); FAB-MS:MH+, 697;NMR (CDCI3)8
ppm: 0.88 (t, 3H,CH3),1.24 (bs, 26H,CHz),1.4 (s, 9H), 1.68-1.79 (bs, 4H, (3
and, CHz Arg), 1.95-2.1 (bs, 4H, (3and,CHz Pro), 2.17 (t, 2H,CO-CHz),
3.4 (bs, 2H, 8CHz Pro), 3.36 (bs, 6H,NH-CHzCHzNH and 8CHz Arg),
4.31 (m, 2H, aCHs),5.7-8.24 (bh, NH).
.'
Preparation of Boc-Lys(Z)-Pro-Arg(NOz)-HN-CHz-CHr
NH-CO-C15H31 (V)
Boc-Lys(Z)-OH (1.6 g, 4mM) and HOBt (0.68 g, 4.5mM) are dis-
solved in dry DMF (25 ml), and the solution is cooled to 0°. A solution
of dipeptide amine H-Pro-Arg(NOz)-HN-CHz-CHz-NH-CO-C15H3b ob-
tained by treatingIV (4 mM) with 4N HCI/dioxane and subsequent neu-
tralization withN-methylmorpholine, is added to the above mixture. After
5 min, diisopropylethyl amine (0.5 ml) and BOP reagent (2.2 g, 4.5mM;
Novabiochem) are added to the reaction mixture, and the stirring is
continued for another 4 h. Solvent is removed under reduced pressure,
and the residue is extracted in ethylacetate (50 ml x 3). The organic layer
is washed with 5% citric acid (3 x 20 ml), saline (3 x 20 ml), 5% NaHC03
(3 x 20 ml), and finally with saline. It is dried over anhydrous sodium
sulfate and concentrated under reduced pressure to obtain an oily residue.
The residue is crystallized with ethyl acetate/hexane to obtain V as a white
solid. Yield: 2.7 g (72%). It is characterized by mass and NMR spectrosco-
py. M.P. 103-105°; [a]Dz5-12.4 (c = 1, DMF); FAB-MS: MH+, 960; NMR
(CDCI3) 8 ppm: 0.88 (t, 3H,CH3),1.24 (bs, 26H,CHz), 1.4 (s, 9H), 1.45-
1.82 (bs, 6H, (3,"and 8CHz Lys), 1.68-1.79 (bs, 4H, (3and,CHz Arg),
1.95-2.1 (bs, 4H, (3and,CHz Pro), 2.17 (t, 2H,CO-CHz), 3.21 (bs, 2H,c:
CHz Lys), 3.4 (bs, 2H, 8CHz Pro), 3.36 (bs, 6H,NH-CHz-CHz-NH and
8 CHz Arg), 4.3-4.81 (m, 3H, aCH), 5 (s, 2H,CHz), 7.3 (s, 5H,CH
aromatic), 5.7-8.24 (bh,NH).
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Preparation of Boc- Thr(Bz)-Lys(Z)-Pro-Arg(NOz)-HN-CHrCHrNH-
CO-C15H31 (VI)
Boc group from V (2.7 g, 2.8mM) is removed using 4N HCl/dioxane in
the usual manner, and the resulting amine hydrochloride is neutralized
with N-methyl morpholine (Sigma-Aldrich) in dry DMF (25 ml). To this
solution, Boc-Thr(Bz)-OH (0.86 g, 2.8mM) and HOBt (0.45 g,3mM) are
added, and the reaction mixture is stirred at 0°. After 5 min, diisopropy-
lethyl amine (0.5 ml; Sigma-Aldrich) and BOP reagent (1.7 g, 3.5mM)
are added, and stirring is continued for 4-5 h. Solvent is removed under
reduced pressure, and the residue is extracted in ethylacetate (3 x 50 ml).
The organic layer is washed with 5% citric acid (3 x 20 ml), saline (3 x
20 ml), 5% NaHC03 (3 x 20 ml), and finally with saline. It is dried over
anhydrous sodium sulfate and concentrated under reduced pressure to
obtain an oily residue. The crude product is subjected to silica gel column
chromatography using 3% MeOH in chloroform as the eluent to obtain
2.1 g (62%) chromatographically homogeneousVI. It is characterized
by mass and NMR spectroscopy. M.P. 82-83°; [a]DZ5-19.5 (c = 1.2,
DMF); FAB-MS: MH+ 1150; NMR (CDCh) 8 ppm: 0.88 (t, 3H,CH3),
1.24 (bs, 26H,CHz),1-4 (s 9H), 1.44 (s, 3H,CH3Thr), 1.45-1.82 (bs, 6H, /3,
"I,and 8CHzLys), 1.68-1.79 (bs, 4H, /3and "ICHz Arg), 1.95-2.1 (bs, 4H, /3
and "ICHz Pro), 2.17 (t, 2H,CO-CHz), 3.21 (bs, 2H,E:CHz Lys), 3.4 (bs,
2H, 8CHz Pro), 3.36 (bs, 6H,NH-CHz-CHz-NH and 8CHz Arg), 4.3-4.81
(m, 4H,a CH), 5-5.1 (2s, 4H,CHz), 7.3-7.4 (2s, lOH, aromatic CH),
5.7-8.24 (bh, NH).
Preparation of Thr-Lys-Pro-Arg-NH-CHrCHrNH-CO-C15H31 (I)
CompoundVI (0.92 g, 0.8mM) is subjected to acidolysis using4-N
HCl/dioxane to remove the Boc group of the Thr residue. The hydrochlo-
ride salt is then subjected to catalytic hydrogenation over palladium
black for 20 h in glacial acetic acid. Solvent is removed under reduced
pressure, and the residue is crystallized using anhydrous methanol/ether
two times to obtain a chromatographically homogeneous white powder.
It is characterized by NMR and FAB-MS. Yield: 0.51 g, (80%). M.P.
149-151° (d); [a]DZ5-38.6 (c = 0.7, DMF); FAB-MS: MH+, 781; NMR
(d6-DMSO)8 ppm: 0.85 (t, 3H,CH3), 1.24 (bs, 26H,CHz), 1.44 (s, 3H,
CH3Thr), 1.45-1.82 (bs, 6H, (3,"I,and 8CHz Lys), 1.68-1.79 (bs, 6H, (3and
Y CHz Arg and (3CHz alkyl), 1.95-2.1 (bs, 4H, (3and "ICHz Pro), 2.04 (t,
2H, CO-CHz), 3.08 (bs, 2H,E:CHz Lys), 3.4 (bs, 2H, 8CHz Pro), 3.36 (bs,
6H,NH-CHz-CHz-NH and 8CHzArg), 4.18-4.51 (m, 4H,a CH), 7.24-8.80
(bh, NH).
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Preparation of Liposomes
Liposomes are prepared from egg phosphatidylcholine (PC) and cho-
lesterol (CH) by sonication except in the case of rifampin (RFP)-
incorporated liposomes (Agarwalet l.,1994). Tuftsin is grafted in the
liposome bilayer by mixing 7-8% of I by weight of PC in the above
mixture. Quantities greater than 7-8% are not well tolerated by the lipo-
some bilayer, whereas lower quantities are inadequate to give optimal
results. In case of RFP-incorporated liposomes, only PC is used as the lipid
component, as the presence of CH in the lipid mixture reduces the amount
of RFP intercalation within the bilayer (Agarwalet al.,1994). Detailed
procedures for preparation of tuftsin-bearing liposomes for studies of their
interactions with PMN leukocytes, for modulating the nonspecific host
resistance against infections, for delivering antileishmanial, antitubercular,
and antifungal drugs to macrophages and monocytes are given below.
..
Preparation of Liposomes for Studies of Interactions with
PMN Leukocytes
To monitor the interactions between the tuftsin-grafted liposomes and
macrophages/monocytes/PMN leukocytes, the liposomal membrane is la-
beled with [14C]PC to determine the extent of exchange/transfer of lipids
between the liposomes and the cells, and the fluorescent dye 6-carboxy-
fluorescein (6-CF) (Ralstonet al.,1981) is entrapped as the model solute to
monitor the extent of solute leakage caused by liposome-cell interactions.
Thus, small unilamellar liposomes are prepared from PC (15jtmol),CH
(7.5 jtmol),traces of [14C]PC (about 10 jtCi), and 6-CF (0.2M) with or
without I (7-8% by PC weight) in 0.8 ml Tris-buffered saline (10mM Tris
containing 150mM NaCl, pH 7.4) or sucrose-supplemented Tris-buffered
saline [10mM Tris containing 150mM NaCl, 44mM sucrose, and 5mM
ethylenediaminetetracetic acid (EDTA), pH 7.4] by probe sonication
(Singhalet al.,1984). Typically, a solution of lipids in chloroform is dried
in a glass tube under a slow jet of oxygen-free nitrogen gas, resulting in the
formation of a thin lipid film on the wall of the tube. Final traces of solvents
are removed after leaving the tubein vacuofor 1-2 h. The lipid film is
dispersed in 0.8 ml Tris-buffered saline. The tube is flushed with nitrogen
and stoppered. It is vortexed at35-40°for 20 min. The lipid dispersion so
obtained is transferred to a cuvette and sonicated (1-1.5 h) under nitrogen
using a probe-type sonicator to obtain an optically clear suspension. The
sonicated preparations are centrifuged at 1O,500gfor 1 h at5°.Only the
liposomes found in the top two thirds of the supernatant are used. Free and
liposomal 6-CF are separated by gel filtration over a Sephadex 0-50
!
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column (1.4 x 20 cm), using Tris-buffered saline as the eluting buffer.
Liposome-rich fractions are pooled together and used in further experi-
ments. The outer diameter of liposomes is determined by negative-staining
electron microscopy.
The extent of incorporation of I in the liposome bilayer is estimated as
follows. To an aliquot (20j.tl)of PCICH liposomes containing I are added
580 j.tlphosphate buffer (10mM, pH 8.5), 20j.tltrinitrobenzenesulfonic
acid (1.5% in 0.8M NaHC03, pH 8.5), and 200j.tlTriton X-100 (1% in
0.8 MNaHC03, pH 8.5) or buffer. It is mixed and then incubated in the
dark at 18-20° for 1 h. After this period, the reaction is stopped by adding
400 j.tlHCI (1.5M). The absorbance for yellow color thus obtained is read
at 410 nm. Quantities of I incorporated in the bilayers are calculated from
the standard curve, which is drawn by reacting varying amounts of I with
trinitrobenzenesulfonic acid under identical conditions. The absorbance at
410 nm is linear with concentration to at least 0.8 absorbance units. The
amounts of I incorporated into the liposome bilayer are over 95%, and
about 60% of this amount is localized in the outer monolayer.
<,
Preparation of Liposomes to Increase Nonspecific Host Resistance
against Parasitic and Fungal Infections
Liposomes are prepared from equimolar amounts of PC and CH with
or without I (8% by weight of PC) in Tris-buffered saline (10mM Tris
containing 150mM NaCl, pH 7.4) by probe sonication, as described above.
The sonicated preparation is centrifuged at12,000gfor 30 min (10°) to
sediment undispersed lipids and titanium particles. The amount of I
incorporated in the liposome bilayer is estimated as described above.
Preparation of Liposomes as Vehicles to Deliver RFP in
Mycobacteriumtuberculosis-Infected Mice
Mycobacterium tuberculosisresides and proliferates primarily within
mononuclear phagocytes. Therefore, delivery of antitubercular drugs, like
RFP, through tuftsin-bearing liposomes should help to enrich this drug
within the diseased cells, which in turn may result in reduction of the drug
dose, leading to reduced RFP toxicity (Raleigh, 1972). Tuftsin-bearing ~
liposomes are thus prepared by incorporating RFP in both the bilayers
and internal aqueous compartment of the liposomes.
Typically, PC (62.5 j.tmol), RFP (0.61 j.tmol), and I (7-8% by PC
weight) are dissolved in chloroform methanol (1:1, v/v). The solution is
dried in a glass tube under a slow jet of oxygen-free nitrogen, resulting in
the formation of a thin lipid film on the wall of the tube. Final traces of
the solvent are removed after leaving the filmin vacuoovernight at 4°.
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The lipid film is dispersed in 1.5 ml of phosphate-buffered saline (PBS;
10 mM phosphate containing 150mM NaCI, pH 7.4) and vortexed at
35-40° for 15-20 min. The lipid dispersion thus obtained is transferred to
a cuvette and sonicated for 30 min under oxygen-free nitrogen, using a
probe-type sonicator. The sonicated preparation is centrifuged at12,000g
for 30 min to remove titanium particles as well as the undispersed or poorly
dispersed lipids. The supernatant is carefully removed and gel filtered
through a Sephadex G-50 column (40 x 1.5 cm) using PBS as the eluent
to separate liposome-associated RFP from free RFP. Liposomes are eluted
in the void volume. The liposome-rich fractions are pooled together and
concentrated in an Amicon Centriflo CF-25 cone. The outer diameter of
liposomes is determined by electron microscopy.
RFP is estimated by measuring its absorbance at 334 nm. The amount
of liposorne-associated drug is determined after lysing the liposomes with
Triton X-lOO (1%). The RFP absorbance at 334 nm is found to remain
unaffected by the presence of liposomes and the detergent and is linear at
least up to100/Lglmlof RFP. About 28-32% of RFP is found to be
incorporated in the unilamellar liposomes.
To determine whether RFP is entrapped or intercalated in liposomes,
the above liposome preparation is frozen under liquid nitrogen and imme-
diately thawed. The preparation is then gel filtered again over a Sephadex
G-50 column (40 x 1.5 cm). RFP elutes under two different peaks. The one
in the void volume corresponds to the liposomal form while the other
corresponds to the free form, suggesting that the drug resides in both the
internal aqueous space and the lipid bilayer.
.
Preparation of Liposomes as Drug Carriers in Treatment ofLeishmania
donovaniandAspergillusInfections
Amphotericin B (Amp B) is a very effective drug for treatment of leish-
manial infections that are resistant to treatment with antimonials and fungal
infections including aspergillosis. Fungal pathogens, unlikeL. do ovani,do
not reside within monocytes and macrophages. It is thought that delivery of
Amp-B through tuftsin-bearing liposomes concentrates the drug within
macrophages, which migrate to fungally infected lesions and serve as a drug
depot, making available high concentrations of the drug in the affected region.
Amp-B-Ioaded liposomes are prepared from PC and CH (molar ratio
7:3) by probe sonication. Typically, PC (49 /Lmol), CH (21 /Lmol), Amp B
(1.0 mg), and I (7-8% by weight of PC) are dissolved in a round-bottom
flask in a minimum volume of chloroform/methanol (1:1, v/v). The solvents
are carefully removed under reduced pressure so that a thin film is formed
on the wall of the flask. Final traces of solvents are removed by leaving the
..
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flaskin vacuoat 4° overnight. The dried lipid film is hydrated with 150mM
sterile saline (2 ml) under vigorous stirring for 1 h under a nitrogen atmo-
sphere in a bath-type sonicator. The lipid dispersion thus obtained is
dialyzed against normal saline for 24 h in the dark at 4°. The dialyzed
preparation is centrifuged at10,000gfor 1 h at 4° to remove traces
of undispersed lipids. The supernatant is analyzed for both Amp-B and ~-
tuftsin.
The amount of liposome-intercalated Amp B is determined by measur-
ing its absorbance at 405 nm. The intercalation efficiencies of Amp B in
tuftsin-bearing liposomes and tuftsin-free liposomes are about 95% and
85%, respectively. The extent of tuftsin incorporation is estimated as
described above.
Interactions of Tuftsin-Bearing Liposomes with Blood Cells
Specific interactions of tuftsin-bearing liposomes with blood cells are
studied by incubating the liposomes with the respective cell population
(PMN leukocytes, lymphocytes, erythrocytes, etc.) at 37° and then measur-
ing the transfer/exchange of lipids between the liposomes and cells as well as
the solute leakage caused by the interaction of liposomes with cells. These
studies show that the tuftsin-bearing liposomes interact specifically with
PMN leukocytes, monocytes, and macrophages, but not with lymphocytes
or erythrocytes under identical conditions (Singhalet aI., 1984).
PMN leukocytes and lymphocytes are isolated from freshly drawn rat
blood using a Ficoll-Paque gradient. Erythrocytes are isolated from rat
blood by simple centrifugation. The detailed procedures are given below
(Singhalet al., 1984).
Isolation of Lymphocytes and PMN Leukocytes
Heparinized rat blood (lO IU/ml blood) is centrifuged at lOOOgfor
lO min, and the plasma is removed. The cells are suspended in Hanks'
balanced salt solution (137mM NaCl, 37mM KCI, 1.0mM CaClz.2HzO,
0.41 mM MgS04.7HzO, 0.50mM MgClz.6HzO, 0.44mM KHzP04,
0.34 mMNazHP04.2HzO, 5.55mM glucose, 4.16mM NaHC03, pH 7.4)
to 50% hematocrit. One milliliter of this suspension is layered on top of
1 ml Ficoll-Paque (Pharmacia product). It is centrifuged at300gfor 15 min
at 20 :I: 2°. The top layer containing lymphocytes is removed and washed
several times with Hanks' balanced salt solution. Any contaminating ery-
throcytes are removed by treating one volume of lymphocytes with seven
volumes of ammonium chloride (150mM, pH 7.4) for 5 min at 20°. The
mixture is centrifuged, and the cell pellet is washed three times with Hanks'
-
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balanced salt solution. The cell viability is determined by Trypan Blue
exclusion; usually over 95% of the cells are viable. The purity of the cells
is determined in a thin smear stained with Leishmann stain. These cells
are contaminated with 5-7% of PMN leukocytes and monocytes. Without
any further purification, these cells are used in further experiments after
suspending in the above buffer (3.6-4.0 x 107 cells/ml).
The second layer formed in the Ficoll-Paque gradient mainly consists of
PMN leukocytes. It is carefully aspirated and washed three times with
Hanks' balanced salt solution. Contaminating erythrocytes are removed
by the ammonium chloride treatment, but it is not necessary to remove
the contaminating lymphocytes (25-30%) from the PMN leukocytes for
the study. The viability of these cells is >95%. The cells are suspended in
the above buffer (3.6-4.0 x 107 cells/ml) and used within 1 h.
Isolation of Erythrocytes
Heparinized rat blood is centrifuged at 1000g for 5 min. Plasma
and buffy coat are removed. The pellet is washed several times with
sucrose-supplemented Tris-buffered saline. The washed cells are sus-
pended in buffer (3.6-4.0 x 107cells/ml) and used immediately in further
experiments.
.,
Interactions of Liposomes with PMN Leukocytes
Liposomes (0.13-2.5 f.lmol lipid P/ml) are mixed with PMN leuko-
cytes (1.8-2.0 x 107cells/ml) in Hanks' balanced salt solution. The mixture
is incubated at 37° for 1 h in a shaking waterbath. After incubation
is complete, the cells are harvested by centrifugation. The cell pellet is
repeatedly washed with Hanks' balanced salt solution until the super-
natant is free from radioactivity. The amounts of radioactivity and 6-CF
in the cell pellet are assayed after disrupting the cells with Triton X-100
(1% final concentration). The 6-CF fluorescence is monitored by using
excitation and emission wavelengths of 490 and 520 nm, respectively.
Recovery of cells is about 90% and >95% are viable at the end. To
determine the effect of incubation temperature on uptake of liposomes
by the leukocytes, liposomes (2 f.lmollipid P/ml) are also incubated with
PMN leukocytes (1.8-2.0 x 107 cells/ml) at 0° for different periods of
time. After incubation is complete, the cells are processed, and the
amounts of radioactivity and 6-CF associated with the cell pellet are
determined.
Free 6-CF is also incubated with the cells under identical conditions.
About 0.01% of the total dye remains bound to the cell pellet.
..
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Interactions of Liposomes with Lymphocytes
Liposomes (2 p,mollipidP/m!)are mixed with lymphocytes (1.8-2.0 x
107/ml)in Hanks' balanced salt solution, and the mixture is incubated for
different periods of time. After incubation is complete, the cells are washed
and assayed for radioactivity and 6-CF.
Interactions of Liposomes with Erythrocytes
Liposomes (2 p,mollipidP/m!)are mixed with erythrocytes (1.8-2.0 x
107/ml)in sucrose-supplemented Tris-buffered saline, and the mixture is
incubated for different periods of time. After completing the incubation,
the cells are washed and assayed for radioactivity. In this case, 6-CF cannot
be measured due to quenching of its fluorescence by hemoglobin.
'".
Treatment of Experimental Animals with Tuftsin-Bearing Liposomes to
Enhance Their Nonspecific Resistance to Infections
To increase the nonspecific resistance of experimental animals to para-
sitic infections, tuftsin-bearing liposomes are given intravenously for 3
consecutive days prior to infection (day -3 to day -1). Normally, the dose
given is 50 ng tuftsin per day per animal, but this dose may vary depending
on the type of infection. Animals are infected on day zero. Under these
conditions, animals resistPlasmodium berghei(Gupta et aI., 1986),
L. donovani(Guruet al.,1989), and to some extentAspergillus fumigatus
(Owaiset al.,1993) infection, but no effects are seen on the course of
M. tuberculosisnfection under identical conditions.
Treatment of Leishmanial, Tuberculosis, and Aspergillosis Infections
Using Tuftsin-Bearing Liposomes as Drug Carriers
RFP-Ioaded tuftsin-bearing liposomes are used to treatM. tuberculosis
H37Rv infections in Swiss albino mice. Various doses of drug-loaded tuft-
sin-bearing liposomes and drug-loaded but tuftsin-free liposomes and the
free drug are delivered intravenously postinfection. The course of infection
is determined by measuring the bacilli load in lungs, livers, and spleens,
as well as the mean survival times of animals. The numbers of bacilli in
lungs, livers, and spleens of mice are quantitated by measuring colony-
forming units (cfu). The efficacy of RFP is considerably improved upon its
administration in tuftsin-bearing liposomes compared with tuftsin-free li-
posomes. Consistently, administration of repeated doses of RFP in tuftsin-
bearing liposomes shows significantly better antitubercular effects than the
administration of a single dose (Agarwalet al., 1994).
...
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AmpB-Ioaded tuftsin-bearing liposomes are used to treatL. donovani
infections in golden hamsters and alsoA. fumigatusinfections in BALB/c mice.
The liposome-associated drug is administered intravenously in both cases
(Agrawalet af.,2002; Owaiset at.,1993). The drug loaded in tuftsin-bearing
liposomes as well as the free drug are given to the control group of animals.
While the drug efficacy in leishmanial infections is assessed by measuring
the parasite load in spleens of the infected animals, the efficacy of Amp B in
A. fumigatusinfections isdetermined by measuring both the fungal load (cfu) in
various organs and survival times of the treated animals. Antileishmanial and
antifungal effects of Amp B are seen to be considerably better if it is adminis-
tered in tuftsin-bearing liposomes as compared to tuftsin-free liposomes or in
the free form (Agrawalet af.,2002; Owaiset af., 1993).
Concluding Remarks
Tuftsin is a well-known macrophage activator tetrapeptide that specifi-
cally binds monocytes, macrophages, and PMN leukocytes. This activity of
tuftsin is further increased upon its incorporation in liposomes, after attach-
ing a sufficiently long hydrophobic anchor at its C-terminus. The tuftsin-
bearing liposomes not only enhanced the nonspecific host's resistance
against a variety of pathogens but also helped in significantly boosting the
chemotherapeutic potential of a number of drugs if delivered after their
encapsulation in these liposomes. These studies thus clearly demonstrate
the usefulness of this tetrapeptide in augmenting the chemotherapeutic
potential of antiparasitic, antitubercular, and antifungal drugs by virtue of
its ability to home the drug-loaded nanoparticle-like systems (e.g., lipo-
somes) to monocytes and macrophages and also to simultaneously stimulate
the nonspecific killer activity of these cells against pathogens.
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Abstract
Polyene antibiotics (i.e., amphotericin B and nystatin) have been
incorporated into lipid-based delivery systems to decrease their toxicity
and enhance their therapeutic index, the most common being liposomes.
This chapter describes the protocols for preparing liposomal amphotericin
B and determining the efficacy and toxicity of the formulations in animals.
Furthermore, methods for determining the pharmacokinetics and drug
distribution after administration of amphotericin B in lipid-based delivery
systems are discussed. Procedures for comparing the toxicity of different
amphotericin B formulations in cell culture studies are also elucidated.
Introduction
Amphotericin B and nystatin are polyene antibiotics. They are effective
for treatments of both presystemic and systemic fungal infections. These
widely used antibiotics are derived from fermentation byS reptomyces.
Polyene antibiotics are also known to induce renal toxicity (Bolard, 1986;
Georgopapadakou and Walsh, 1996; Meyer, 1992).
METHODS IN ENZYMOLOGY. VOL. 391
Methods Enzymol.391,291-304 (2005)
Gupta, C. M., Puri, A., Jain, R. K., Bali, A., and Anand, N. (1986). Protection of mice against
Plasmodium berghei infection by a tuftsin derivative.FEBS Lett.205,351-354.
Najjar, V. A. (1987). Biological effects of tuftsin and its analogs.Drugs Future12,147-160.
Owais, M., Ahmed, I., Krishnakumar, B., Jain, R. K., Bachhawat, B. K., and Gupta, C. M.
(1993). Tuftsin-bearing liposomes as drug vehicles in the treatment of experimental
aspergillosis.FEBS Lett.326, 56-58.
Owais, M., Misra-Bhattacharya, S., Haq, W., and Gupta, C. M. (2003). Immunomodulator
tuftsin augments antifilarial activity of diethylcarbamazine against experimental brugian
filariasis.J. Drug Target.11,247-251.
Raleigh, J. W. (1972). Rifampin in treatment of advanced pulmonary tuberculosis. Report of a
VA cooperative pilot study.Am. Rev. Respir. Dis.105,397-407.
Ralston, E., Hjelmeland, L. M., Klausner, R. D., Weinstein, J. N., and Blumenthal, R. (1981).
Carboxyfluorescein as a probe for liposome-cell interactions. Effects of impurities and
purification of the dye.Biochim. Biophys. Acta649,133-137.
Singh, S. P., Chhabra, R., and Srivastava, V. M. L. (1992). Respiratory burst in peritoneal
exudate cells in response to a modified tuftsin.Experientia48,994-996.
Singhal, A., Bali, A., Jain, R. K., and Gupta, C. M. (1984). Specific interactions of liposomes
with PMN leukocytes upon incorporating tuftsin in their bilayers.FEBS Lett.178,109-113.
I
Methods Enzymol.391,291-304 (2005)
